8-K: Foghorn Therapeutics Secures New Watertown Headquarters, Exiting Cambridge Facility

Foghorn Therapeutics Inc. has entered into a new long-term lease for a larger facility in Watertown, MA, while simultaneously terminating its existing lease in Cambridge, MA, signaling a strategic relocation and expansion of its operations.

Summary

• Foghorn Therapeutics Inc. (FHTX) has signed a new lease agreement for 72,846 square feet of space at 99 Coolidge Avenue, Watertown, MA, to serve as its principal executive offices, research, development, manufacturing, and related uses.
• The new lease commences on July 16, 2025, with base rent anticipated to begin on October 1, 2026, following a 9.5-month abatement period after the Landlord Work Completion Date (targeted December 15, 2025).
• Annual base rent for the new premises will initially be $3.9 million for the first year (based on 45,000 rentable square feet), approximately $5.2 million for the second year (based on 60,000 rentable square feet), and approximately $6.3 million thereafter, subject to a 3% annual increase starting October 1, 2027.
• The company will also pay a pro rata share of annual operating and tax expenses, estimated at 22.71%, with abated rates of 14.03% and 18.70% during the first and second partial abatement periods, respectively.
• The new lease has an initial term of 108 months (9 years) and includes two successive options to extend for additional five-year periods.
• Concurrently, Foghorn Therapeutics has entered into an agreement to terminate its prior lease for approximately 81,441 rentable square feet at 500 Technology Square, Cambridge, Massachusetts, which was originally scheduled to expire on September 30, 2028.
• The termination agreement sets an outside termination date of December 31, 2026, for the old lease, with earlier termination possible for portions of the premises.
• Rent and other monthly obligations for the Ninth Floor Premises of the old facility are abated from May 1, 2025, through the termination date.
• For the remaining premises of the old facility, monthly payment obligations continue until the New Premises Delivery Date (targeted December 15, 2025); if delayed beyond this date (not due to tenant/force majeure), monthly payments will be reduced to $115,000.00 per month.
• The security deposit for the old lease has been reduced from $1,708,200.00 to $1,250,000.00 and will be returned within 90 days of decommissioning completion or February 1, 2026.
• The company's sublease with Merida Biosciences, Inc. for a portion of the old premises will either terminate if Landlord and Merida enter a direct lease, or continue until September 29, 2028, with Foghorn assigning its rights and obligations to the Landlord from the New Premises Delivery Date.
• Foghorn is not required to remove or restore existing tenant improvements, wires, cables, or non-relocated furniture from the old premises, but must complete decommissioning and a Hazardous Materials Closure Plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company is making a strategic move to a larger, more suitable facility, which is crucial for growth in the biotech sector. The financial terms, while increasing long-term costs, include initial abatements and a reduction in the old lease's security deposit, indicating a managed transition. Potential delays and increased future costs are noted but are typical for such significant operational changes.

Positives

• Securing a new, larger facility (72,846 sq ft) supports potential future growth in research, development, and manufacturing capabilities.
• The new lease includes a significant base rent abatement period (9.5 months) and partial abatement of operating expenses for the first two years, providing initial cost relief.
• Early termination of the prior lease (originally expiring September 30, 2028) allows for a streamlined transition and avoids dual rent obligations for an extended period.
• The reduction of the security deposit on the old lease from $1,708,200.00 to $1,250,000.00 frees up capital.
• Flexibility regarding the Merida Sublease, with the Landlord potentially taking over the direct lease, simplifies Foghorn's exit from the old premises.
• The new facility offers access to shared amenities (conference facilities, fitness center, restaurant) and shuttle service, enhancing employee experience and operational convenience.

Negatives

• The new lease entails significantly higher annual base rent payments in the long term, escalating from $3.9 million to approximately $6.3 million with annual 3% increases.
• The company will be responsible for a substantial pro rata share (22.71%) of operating and tax expenses at the new facility.
• There is no guarantee of continued availability of the shuttle service or operational status of emergency generators and the acid neutralization system at the new facility.
• The company remains responsible for all rent and other amounts due under the prior lease through the applicable termination date, and for decommissioning and HazMat closure of the old premises.

Risks

• Potential delays in the Landlord Work Completion Date for the new premises (targeted December 15, 2025), which could impact relocation timelines and operational continuity.
• If the New Premises Delivery Date is significantly delayed beyond December 31, 2026, Foghorn retains the right to terminate the new lease, which would necessitate finding alternative arrangements and could disrupt operations.
• Increased operational costs associated with the new, larger facility and its associated operating expenses, which could impact financial performance.
• Environmental liabilities related to the decommissioning and Hazardous Materials Closure Plan for the old premises, requiring compliance with all Environmental Requirements.
• Uncertainty regarding the long-term availability and specific routes/schedules of the shuttle service, which could affect employee commuting.
• No guarantee that emergency generators or the acid neutralization system at the new facility will be operational at all times or meet all of Tenant's requirements, potentially impacting critical lab operations.

Future Outlook

The company's future outlook involves consolidating and expanding its operations into a larger, purpose-built facility in Watertown, MA, which is expected to enhance its research, development, and manufacturing capabilities. This strategic relocation aims to support future growth and operational efficiency, with a planned transition period and a target completion date for the new facility's build-out by December 2025.

Industry Context

This relocation is consistent with a broader trend in the life sciences industry, particularly in the Greater Boston area, where companies often seek larger, more modern laboratory and manufacturing spaces to accommodate growth. The move from Cambridge to Watertown, while a short distance, reflects the expansion of the biotech hub beyond traditional core areas, driven by demand for specialized facilities and competitive real estate markets. Alexandria Real Estate Equities, as the landlord for both the old and new facilities, is a major player in providing purpose-built life science real estate, indicating a continued partnership within the industry's specialized infrastructure.

Comparison to Industry Standards

• The new lease at 99 Coolidge Avenue, Watertown, MA, for 72,846 sq ft, is a significant commitment, aligning with the growth trajectory of many mid-to-large-cap biotech firms requiring integrated R&D and manufacturing capabilities.
• The initial base rent of $87.00 per rentable square foot (implied by the $3.9M for 45,000 sq ft and $5.2M for 60,000 sq ft, and $6.3M for 72,846 sq ft) is competitive for high-quality lab and manufacturing space in the Boston/Watertown submarket, especially considering the landlord's work and amenities.
• The 3% annual rent escalation is a standard industry practice for long-term commercial leases in prime biotech clusters, reflecting anticipated inflation and market value appreciation.
• The provision of 1.9 parking spaces per 1,000 rentable square feet is a reasonable ratio for a lab/office facility in a dense urban/suburban area, comparable to benchmarks in similar life science parks.
• The inclusion of shared amenities (conference facilities, fitness center, restaurant) and shuttle service is increasingly common in modern life science campuses, offered by landlords like Alexandria Real Estate Equities to attract and retain tenants, enhancing the overall value proposition beyond just square footage.
• The flexibility to terminate the Merida Sublease and the Landlord's willingness to potentially take over the direct lease with Merida demonstrates a cooperative approach, which is beneficial in complex multi-tenant environments and common in large portfolio landlords like Alexandria.

Related Party Transactions

• The new landlord, ARE-MA Region No. 77, LLC, and the prior landlord, ARE-Tech Square, LLC, are both affiliates of Alexandria Real Estate Equities, Inc. (ARE), indicating a related-party transaction for both the new lease and the termination of the old lease.

Stakeholder Impact

• **Shareholders**: The strategic relocation and expansion into a larger facility could be viewed positively as it supports future growth and operational capacity, though it also entails increased long-term financial commitments.
• **Employees**: Employees will experience a change in commute and work environment due to the relocation from Cambridge to Watertown. Access to new amenities and shuttle services at the new location could be a positive.
• **Customers/Suppliers**: No direct immediate impact on customers or suppliers is indicated, but enhanced R&D and manufacturing capabilities could lead to future benefits.
• **Creditors**: The new lease represents a significant long-term financial obligation, which will be factored into the company's financial health and creditworthiness.

Next Steps

• Completion of Landlord's Work at the new premises at 99 Coolidge Avenue, Watertown, MA, by the target date of December 15, 2025.
• Relocation of principal executive offices, research, development, and manufacturing operations to the new facility.
• Finalization of the decommissioning and Hazardous Materials Closure Plan for the old premises at 500 Technology Square, Cambridge, MA.
• Negotiation and potential execution of a Direct Lease between Landlord and Merida Biosciences, Inc. for the subleased portion of the old premises.
• Ongoing payment of rent and operating expenses for the remaining portions of the old premises until their respective termination dates.

Key Dates

Keywords

Biotechnology, Life Sciences, Real Estate, Lease Agreement, SEC Filing, Corporate Relocation, Laboratory Space, Research and Development, Manufacturing, Cambridge, Watertown, Commercial Property, Facility Management, Alexandria Real Estate Equities